Quick Answer
Emmaus Life Sciences, Inc. reported Total Revenue of $12.45 million for fiscal year 2025.
Emmaus Life Sciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $12.45M -25.2% |
$16.65M -43.7% |
$29.60M +60.9% |
$18.39M -10.8% |
$20.61M -11.0% |
$23.17M +1.8% |
| Revenue (ASC 606) | $12.45M -25.2% |
$16.65M -43.7% |
$29.60M +60.9% |
$18.39M -10.8% |
$20.61M -11.0% |
$23.17M +1.8% |
| Net Income | -$7.49M -16.1% |
-$6.45M -72.9% |
-$3.73M +64.9% |
-$10.62M +33.4% |
-$15.95M -1277.7% |
$1.35M +102.5% |
| Diluted EPS | -$0.12 -20.0% |
-$0.10 -42.9% |
-$0.07 +66.7% |
-$0.21 +34.4% |
-$0.32 | — |
| Total Assets | $21.44M -9.2% |
$23.60M -32.9% |
$35.18M -27.1% |
$48.23M -15.0% |
$56.73M -4.7% |
$59.54M +2.5% |
| Cash and Equivalents | $2.13M +53.1% |
$1.39M -45.5% |
$2.55M +26.0% |
$2.02M -11.3% |
$2.28M -8.4% |
$2.49M +87.6% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | -$63.61M -12.6% |
-$56.48M -18.3% |
-$47.76M -40.1% |
-$34.09M -58.9% |
-$21.45M -315.9% |
-$5.16M +57.9% |
| R&D Expense | $313.0K -52.4% |
$657.0K -44.7% |
$1.19M -31.1% |
$1.73M -58.0% |
$4.11M +70.7% |
$2.41M +10.3% |
| Operating Income | $231.0K +112.2% |
-$1.89M -153.5% |
$3.54M +153.8% |
-$6.59M -7.5% |
-$6.13M -19050.0% |
-$32.0K +99.3% |
| Gross Profit | $11.60M -25.0% |
$15.45M -45.3% |
$28.25M +78.8% |
$15.80M -8.6% |
$17.30M -17.3% |
$20.92M -3.4% |
| Shares Outstanding | 70.19M +9.9% |
63.87M +3.3% |
61.85M +24.7% |
49.58M +0.6% |
49.31M +0.7% |
48.99M +2.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $3.38M | -38.3% | +19.9% |
| Revenue (ASC 606) | September 30, 2025 | $3.38M | -38.3% | +19.9% |
| Net Income | September 30, 2025 | -$2.08M | -213.6% | -82.9% |
| Diluted EPS | September 30, 2025 | -$0.03 | -200.0% | -50.0% |
| Total Assets | September 30, 2025 | $20.76M | -24.1% | -11.1% |
| Cash and Equivalents | September 30, 2025 | $293.0K | -76.7% | -66.9% |
| Long-Term Debt | June 30, 2019 | $615.8K | +6.5% | +1.5% |
| Stockholders Equity | September 30, 2025 | -$59.49M | -10.6% | -6.8% |
| R&D Expense | September 30, 2025 | $50.0K | -65.8% | -10.7% |
| Operating Income | September 30, 2025 | $695.0K | -15.3% | +287.8% |
| Gross Profit | September 30, 2025 | $3.13M | -38.4% | +17.4% |
| Shares Outstanding | September 30, 2025 | 63.87M | +0.0% | +0.0% |
- Emmaus Life Sciences, Inc. reported Total Revenue of $12.45 million for fiscal year 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -25.2% in Total Revenue compared to the prior fiscal year.
- Emmaus Life Sciences, Inc. reported Revenue (ASC 606) of $12.45 million for fiscal year 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -25.2% in Revenue (ASC 606) compared to the prior fiscal year.
- Emmaus Life Sciences, Inc. reported Net Income of -$7.49 million for fiscal year 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -16.1% in Net Income compared to the prior fiscal year.
- Emmaus Life Sciences, Inc. reported Diluted EPS of $0.12 per share (loss) for fiscal year 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -20.0% in Diluted EPS compared to the prior fiscal year.
- Emmaus Life Sciences, Inc. reported Total Assets of $21.44 million for fiscal year 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -9.2% in Total Assets compared to the prior fiscal year.
- Emmaus Life Sciences, Inc. reported Cash and Equivalents of $2.13 million for fiscal year 2025.
- Emmaus Life Sciences, Inc. showed an increase of +53.1% in Cash and Equivalents compared to the prior fiscal year.
- Emmaus Life Sciences, Inc. reported Long-Term Debt of $587.7 thousand for fiscal year 2018.
- Emmaus Life Sciences, Inc. reported Stockholders Equity of -$63.61 million for fiscal year 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -12.6% in Stockholders Equity compared to the prior fiscal year.
- Emmaus Life Sciences, Inc. reported R&D Expense of $313.0 thousand for fiscal year 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -52.4% in R&D Expense compared to the prior fiscal year.
- Emmaus Life Sciences, Inc. reported Operating Income of $231.0 thousand for fiscal year 2025.
- Emmaus Life Sciences, Inc. showed an increase of +112.2% in Operating Income compared to the prior fiscal year.
- Emmaus Life Sciences, Inc. reported Gross Profit of $11.60 million for fiscal year 2025.
- Emmaus Life Sciences, Inc. showed a decrease of -25.0% in Gross Profit compared to the prior fiscal year.
- Emmaus Life Sciences, Inc. reported Shares Outstanding of 70.19 million shares for fiscal year 2025.
- Emmaus Life Sciences, Inc. showed an increase of +9.9% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: